Hepion Pharmaceuticals, Inc. (HEPA)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.15
- As of
Kresmion compiles this page from HEPA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Hepion Pharmaceuticals, Inc. (HEPA): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-09.
See the full HEPA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for HEPA on one page. Preview it with sample data, then open it live with a free account.
Preview the HEPA dossierActive events for HEPA
- mediumEarnings above estimates
Q3-2023: Beat consensus by 13.9% - EPS $-137 vs $-159.12 estimate
- mediumEarnings above estimates
Q4-2023: Beat consensus by 9.8% - EPS $-121 vs $-134.13 estimate
- mediumEarnings below estimates
Q2-2023: Missed consensus by 8.6% - EPS $-184 vs $-169.4898 estimate
- mediumEarnings above estimates
Beat consensus by 13.9% - EPS $-137 vs $-159.12 estimate
- mediumEarnings above estimates
Beat consensus by 9.8% - EPS $-121 vs $-134.13 estimate
FREE, NO ACCOUNT
Every event on HEPA, as it fires
New filings, 13F moves and cross asset events on HEPA land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Historical quarters remain available above.
Recent SEC filings, HEPA
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
HEPA against its peers
HEPA's return on equity of -310.3% ranks in the 25th percentile of 17 Biotechnology sub-industry peers, fiscal periods ending between 2025-03-31 and 2026-06-30.
| Metric | HEPA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 710968 | n/a | 12 |
| Gross margin | n/a | 71.3% | n/a | 5 |
| Operating margin | n/a | -1151.0% | n/a | 10 |
| Net margin | n/a | -1120.7% | n/a | 10 |
| Return on equity | -310.3% | -202.7% | 25 | 17 |
Peers (22): BIVI, ASBP, ACTU, CNSY, AAGH, AEON, SYBX, TCRX, DARE, LPCN, HIND, ICU, ADIL, KTTA, RKTO, KPTI, TVRD, CKDXF, GTBP, PBM, CLRB, BCDA. Left out: VICP (period gap), RADX (no annual filing), CTXR (no annual filing). Fiscal periods ending between 2025-03-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (HEPA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow HEPA on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to HEPA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.